Dr. David Rosenberg MD
Chief of Psychiatry and Psychology, CHILDREN'S HOSPITAL OF MICHIGAN
Member of the Healthcare Council
Council Member Biography
David Rosenberg, MD, is a tenured professor and Miriam L Hamburger Endowed Chair of Psychiatry at Wayne State University and the Children's Hospital of Michigan. He is a board certified general and adult psychiatrist and pediatric psychiatrist. Dr. Rosenberg has authored first ever textbook on pediatric psychopharmacology and has over 100 other publications. He has been the recipient of many honors and awards including National Institute of Health grants awards. Dr. Rosenberg’s clinical and research area of expertise includes patients with ADHD, depression, bipolar disorder, anxiety and obsessive compulsive disorder. He has expertise in psychopharmacology, neuro-pharmacology, new drug development, brain imaging and pharmaco-genetics of neuro-psychiatric disorders, and predicting treatment response. Dr. Rosenberg has conducted clinical trials of new medications for adult and child psychiatry. (This is me - Update Profile)
Employment History
- 2006 - Unspecified
- Professor and Endowed Chair of Psychiatry, WAYNE STATE UNIVERSITY
- 2004 - Unspecified
- Chief of Psychiatry and Psychology, CHILDREN'S HOSPITAL OF MICHIGAN
- 1994 - 1996
- Assistant Professor, University of Pittsburgh Medical Center
GLG NewsSM Analyses by David Rosenberg(?)
Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
-
Neuronal nicotinic receptor agonists potential breakthrough for ADHD research
May 12, 2008
Abbott Scientists Present A New Approach for Treating Attention-Deficit Hyperactivity Disorder | biz.yahoo.com
1. Effective treatment for ADHD 2. Well tolerated with few side effects 3. Help with smoking, a big problem in ADHD patients important 4. Advantage in not being Schedule II may be helpful
-
Important New Data for Children and Adolescents
May 12, 2008
FDA Approves Strattera® for Maintenance of ADHD in Children and Adolescents | newsroom.lilly.com
1. Important new finding given safety concerns raised about this and other treatmetns 2. Nice to have data back up what has long been done clinically 3. Stimulants still first line and lack of active comparator trial
-
Exciting new treatment for OCD and Social Anxiety Disorder
March 7, 2008
FDA Approves Luvox CR (Fluvoxamine Maleate) Extended-Release Capsules for the Treatment of Social Anxiety Disorder and Obsessive Compulsive Disorder | pharmalive.com
1. Controlled release preparations are often better tolerated with fewer side effects than immediate release preparations 2. OCD and SAD are severe, highly prevalent and chronically disabling conditions 3. Despite presence of SSRIs and other treatment, e.g, cognitive behavioral therapy, up to 1/3 of patients with OCD or SAD do not respond to currently available treatments and among responders many do so only partially
-
FDA Approval of Abilify for Pediatric Bipolar disorder is a Major Advance
March 7, 2008
1. Despite common use of multiple psychotropic medications for bipolar disorder in youth, there are few FDA-approved treatments 2. Abilify is one of the safest and best tolerated of the atypical antipsychotics with fewer side effects than some of the other atypical antipsychotic medications 3. This treatment offers new hope to many children and their families
-
More questions raised than answers
February 5, 2008
Chantix And Suicide: The Latest Numbers | www.pharmalot.com
No good data that Chantix is associated with suicide Need more controlled research to answer questions Scary adverse events are not the same as side effects directly linked to medication
Leading institutions connect with David Rosenberg through GLG
GLG Study Groups with David Rosenberg(?)
| Study Group Name | No. Members |
|---|---|
| Experts in the Leisure & Lodging Council | 4887 |
| Experts in the Automotive Council | 3422 |
| Psychiatrists | 1535 |
| Psychiatrists (US) | 1136 |
| Generic Drug Economic Experts | 766 |
GLG Live Meetings with David Rosenberg(?)
David Rosenberg has not participated in any GLG Live Meetings.